【摘要】 慢性心力衰竭（chronic heart failure，CHF）是各种心脏疾病导致心功能不全的一种综合征。各种病因的心脏病发展到终末阶段都将导致心力衰竭，且病情危重，死亡率高。心力衰竭时，肾素血管紧张素醛固酮(ALD)系统被激活，导致心室重构。故是否有效地抑制ALD系统是决定心力衰竭治疗效果的关键^[1] 。目前CHF患者，除按传统方法应用强心、利尿等治疗措施外，肾素血管紧张素转换酶抑制剂的广泛应用使心力衰竭患者的病情得到有效控制或缓解。但是血管紧张素Ⅱ(AngⅡ) 受体AT1的拮抗剂在心力衰竭中的应用尚不明确。本研究通过观察缬沙坦治疗心力衰竭患者的临床疗效，以了解血管紧张素Ⅱ(AngⅡ)受体AT1的拮抗剂在心力衰竭治疗中的作用。

    Effect of Valsartan on chronic heart failure   WU Zhong, QIAO Ping, WANG Sheng, LIAO Wang, WU Qingliu, WANG Wei, SU Zhetan. Department of Cardiology, People’s Hospital of Hainan Province, Hainan Haikou 570311，China

    Abstract：Objective  To observe the effect of valsartan on chronic heart failure.   Methods  Fiftyeight chronic heart failure patients were randomly divided into two groups: 30 patients treated with Valsartan (Valsartan group) and 28 patients received stardard therapies plus without Valsartan or any other angiotensinⅡ type 1 receptor blockade (control group). Both groups underwent echocardiography before and 6 months after treatment.   Results  In Valsartan group, left ventricular enddiastolic volume(LVEDV) [(102.6±25.6)ml vs. (117.2±28.5)ml, P＜0.05]and left ventricular endsystolic volume(LVESV) [(53.1±20.6)ml vs. (66.4±28.7)ml, P＜0.05] were significantly decreased after treatment while left ventricular ejection fraction(LVEF) [(56.1±9.6)% vs.( 47.4±13.2)%, P＜0.01] was significantly increased. After one year’s follow up, the rate of recurrent heart failure in Valsartan group was significantly lower than in control group (24.0% vs. 46.7%，P＜0.05).   Conclusions  Valsartan can prevent ventriclular remolding and decrease recurrent heart failure.

    Key words：  Valsartan;  Heart Failure